Endocrine Therapies in Breast Cancer

Breast cancer is one of the leading causes of cancer mortality in womenworldwide, and the risk of disease recurrence continues despite improvements inscreening and treatment. For patients with hormone receptor-positive breastcancer, some form of endocrine therapy is central to the management of theirdisease. Tamoxifen has long been the mainstay of endocrine therapy in this groupof patients. However, there is mounting evidence showing that the aromataseinhibitors are able to reduce overall oestrogen levels and appear to be bettertolerated over a long term than tamoxifen. New and emerging indications for thearomatase inhibitors are providing clinicans (and patients) with alternativetreatment options with differing side effect profiles.Part of the Oxford Oncology Library, this pocketbook will summarise the latestevidence-based and practical information on the use of endrocrine therapies inthe management of breast cancer (early stage, metastatic disease, and preventionof disease). With contributions from leading oncologists from the MD AndersonCancer Center, the book covers the range of endocrine therapies currentlyavailable to clinicians including ovarian ablation, anti-estrogens, aromataseinhibitors, fulvestrant, progestins, androgens, and combination endocrine andchemotherapy. The book also includes useful chapters on the identification andoptimal selection of patients for endocrine therapy as well as the role ofendocrine treatments in the prevention of breast cancer.This book will serve as an invaluable reference for all health careprofessionals involved in the management of patients with breast cancer.Buzdar, Aman U. is the author of 'Endocrine Therapies in Breast Cancer ', published 2007 under ISBN 9780199218141 and ISBN 0199218145.